Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Almirall, S.A.
With
Forest Laboratories
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult male or female patients aged ≥40 years with stable moderate-to-severe COPD according to the GOLD Guidelines classification (grades II and III): forced expiratory volume in 1 second (measured between 10 to 15 minutes post-inhalation of 400 μg of salbutamol) is 30%≤FEV1\<80% of the predicted normal value
Patients naïve to both study inhaler devices, Genuair® and Breezhaler®, for at least 2 years
Agreement to participate and voluntarily sign the informed consent form
You may not be if
Patients with other clinically significant uncontrolled chronic diseases, particularly body malformations or diseases affecting coordination and/or motor system
Patients unable to read product package instructions and answer patient reported questionnaires (PASAPQ)
Patients with any other serious or uncontrolled mental health problems
Patients currently participating in other randomised clinical studies
Patients with COPD exacerbation within 6 weeks before Visit 1 and patient hospitalised for COPD exacerbation within 3 months prior to Visit 1
Patients with any other conditions that, in the investigator's opinion, might indicate the patient to be inappropriate for the study
